JAK抑制剂间转换治疗重度斑秃的多中心回顾性研究
本研究多中心回顾性分析108例重度斑秃患者,在至少6个月口服JAK抑制剂治疗后转换用药。结果显示48.8%患者第二种JAK抑制剂达到SALT≤20,32.6%达到SALT≤10;转换策略可行,既往应答可指导治疗顺序。
要点
- 重度斑秃患者转换JAK抑制剂后近半数可达SALT≤20
- 对第一种JAK抑制剂有应答者转换后应答概率更高
- 转换治疗不良事件轻微,与既往报道一致
核心结论
- JAK抑制剂间转换是重度斑秃患者的可行策略,尤其对既往JAK抑制剂有应答者。
- 既往应答情况可能有助于指导治疗顺序。
研究设计与样本
- 多中心回顾性研究,纳入108例重度斑秃患者,在至少6个月口服JAK抑制剂治疗后转换用药。
- 使用脱发严重程度工具(SALT)评估治疗应答,采用多变量逻辑回归分析第二次JAK抑制剂应答的预测因素。
主要发现
- 48.8%的患者在第二种JAK抑制剂治疗中达到SALT≤20,32.6%达到SALT≤10。
- 21例接受第三种JAK抑制剂的患者中,52.4%达到SALT≤20,38.1%达到SALT≤10。
- 不良事件轻微,与既往报道一致。
临床怎么用
- 对于重度斑秃患者,若初始JAK抑制剂治疗应答不佳,可考虑转换为另一种JAK抑制剂。
- 转换决策时可参考患者对既往JAK抑制剂的应答情况。
局限性
- 回顾性设计。
- 治疗方案异质性。
- 可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Janus kinase inhibitors (JAKis) have transformed the treatment of alopecia areata (AA), but not all patients respond to initial therapy. The utility of switching between JAKis in treatment-refractory AA remains underexplored. OBJECTIVE: To evaluate the efficacy and safety of switching between JAKis in patients with severe AA. METHODS: In this multicenter retrospective study, we analyzed 108 patients with severe AA who switched between oral JAKis after a minimum treatment duration of 6 months. Treatment response was assessed using the Severity of Alopecia Tool (SALT). Multivariable logistic regression was used to identify predictors of response to a second JAKi. RESULTS: Overall, 48.8% of patients achieved SALT ≤20 on their second JAKi, and 32.6% achieved SALT ≤10. Of 21 patients who received a third JAKi, 52.4% achieved SALT ≤20 and 38.1% achieved SALT ≤10. Patients who responded to their first JAKi were more likely to respond to a second (odds ratio, 3.33; 95% CI, 1.22-9.68; P = .022). Adverse events were mild and consistent with prior reports. LIMITATIONS: Retrospective design, treatment heterogeneity, and potential selection bias. CONCLUSIONS: Switching between JAKis appears to be a viable strategy for severe AA patients, especially those responding to prior JAKi. Prior response may help guide treatment sequencing.
引用
- Martin A, Chen LC, Kreytak C, et al. Switching between Janus kinase inhibitors for treatment of alopecia areata: A multicenter retrospective review. J Am Acad Dermatol. 2026. PMID: 41621668. doi:10.1016/j.jaad.2026.01.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。